James D. Brooks
Publications
- A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. Adv Anat Pathol. 2013; (1): 39-44
- Comprehensive gene expression changes associated with mouse postnatal kidney development. J Urol. 2013; (6): 2385-90
- Epigenetic changes in histologically normal prostate tissues. J Urol. 2013; (6): 2020-1
- Identification and Characterization of 2 Testicular Germ Cell Markers, Glut3 and CyclinA2. Appl Immunohistochem Mol Morphol. 2013
- Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1. Oncogene. 2013; (1): 70-7
- Treatment and mortality in men with localized prostate cancer: a population-based study in California. The Open Prostate Cancer Journal. 2013: 1-9
- Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res. 2013; (9): 2442-2450
- Deficiency in mammalian histone H2B ubiquitin ligase Bre1 (Rnf20/Rnf40) leads to replication stress and chromosomal instability. Cancer Res. 2012; (8): 2111-9
- Evaluation of SF-1 Expression in Testicular Germ Cell Tumors: A Tissue Microarray Study of 127 Cases. Appl Immunohistochem Mol Morphol. 2012
- Evaluation of putative renal cell carcinoma markers PAX-2, PAX-8, and hKIM-1 in germ cell tumors: a tissue microarray study of 100 cases. Appl Immunohistochem Mol Morphol. 2012; (5): 451-3
- Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer and predicts PSA recurrence. Br J Cancer. 2012; (1): 100-7
- Gene expression changes induced by unilateral ureteral obstruction in mice. J Urol. 2012; (3): 1033-41
- Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012; (2): 877-82
- Methods for registration of magnetic resonance images of ex vivo prostate specimens with histology. J Magn Reson Imaging. 2012; (1): 206-12
- Performance characteristics of prostate-specific antigen in patients undergoing radical prostatectomy. Urology. 2012; (6): 1336-9
- Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene. 2012; (37): 4164-70
- Translational genomics: the challenge of developing cancer biomarkers. Genome Res. 2012; (2): 183-7
- mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer. PLoS One. 2012; (11): e49144
- Comparison of prostate cancer tumor volume and percent cancer in prediction of biochemical recurrence and cancer specific survival. Urol Oncol. 2011 May-Jun; (3): 314-8
- A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer. PLoS One. 2011; (5): e20293
- DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res. 2011; (7): 1017-27
- Integrated genomic analyses of ovarian carcinoma. Nature. 2011; (7353): 609-15
- Length of site-specific positive surgical margins as a risk factor for biochemical recurrence following radical prostatectomy. Int J Urol. 2011
- Small prostate size and high grade disease--biology or artifact? J Urol. 2011; (6): 2108-11
- Smoking and adverse outcomes at radical prostatectomy. Urol Oncol. 2011
- Specificity of brachyury in the distinction of chordoma from clear cell renal cell carcinoma and germ cell tumors: a study of 305 cases. Mod Pathol. 2011; (3): 425-9
- The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study. J Urol. 2011; (2): 465-9
- Adjuvant docetaxel and abbreviated androgen deprivation therapy in patients with high risk prostate cancer The Open Prostate Cancer Journal. 2010: 99-104
- Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology. 2010; (2): 407-13
- Gene expression changes induced by genistein in the prostate cancer cell line LNCaP The Open Prostate Cancer Journal. 2010: 86-98
- Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer. 2010; (2): 152-163
- The distribution of PAX-2 immunoreactivity in the prostate gland, seminal vesicle, and ejaculatory duct: comparison with prostatic adenocarcinoma and discussion of prostatic zonal embryogenesis. Hum Pathol. 2010; (8): 1145-9
- Prognostic significance of prostate cancer originating from the transition zone. Urol Oncol. 2009 Nov-Dec; (6): 592-7
- Alteration of gene expression signatures of cortical differentiation and wound response in lethal clear cell renal cell carcinomas. PLoS One. 2009; (6): e6039
- Apolipoprotein D (APOD) is a putative biomarker of androgen receptor function in androgen insensitivity syndrome. J Mol Med (Berl). 2009; (6): 623-32
- CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma. BMC Clin Pathol. 2009: 9
- Disorders of sex development expose transcriptional autonomy of genetic sex and androgen-programmed hormonal sex in human blood leukocytes. BMC Genomics. 2009: 292
- Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. Int J Cancer. 2009; (9): 2050-9
- Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation. Prostate. 2009; (7): 719-26
- Recommendations for the reporting of surgically resected specimens of renal cell carcinoma. Am J Clin Pathol. 2009; (5): 623-30
- Recommendations for the reporting of surgically resected specimens of renal cell carcinoma: the Association of Directors of Anatomic and Surgical Pathology. Hum Pathol. 2009; (4): 456-63
- Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009; (4): 1043-8
- Temporal changes in gene expression induced by sulforaphane in human prostate cancer cells. Prostate. 2009; (2): 181-90
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; (7216): 1061-8
- Identification of candidate prostate cancer genes through comparative expression-profiling of seminal vesicle. Prostate. 2008; (11): 1248-56
- Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2008; (5): 1472-7
- The impact of tumor volume on outcomes after radical prostatectomy: Implications for prostate cancer screening. The Open Prostate Cancer Journal. 2008: 1-8
- hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature. Am J Surg Pathol. 2008; (2): 205-9
- A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. Nucleic Acids Res. 2007; (8): 2767-76
- A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol. 2007; (4): 467-73
- Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. J Cell Physiol. 2007; (1): 111-21
- Editorial Comments. J Urol. 2007; (6): 2400
- Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor. Cancer Lett. 2007; (1-2): 139-48
- Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 2007; (18): 8504-10
- Intrinsic androgen-dependent gene expression patterns revealed by comparison of genital fibroblasts from normal males and individuals with complete and partial androgen insensitivity syndrome. BMC Genomics. 2007: 376
- Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007; (5): 673-80
- Selenomethionine induced transcriptional programs in human prostate cancer cells. J Urol. 2007; (2): 743-50
- The application of genomic and proteomic approaches to human prostate cancer in developing diagnostic and prognostic markers. Urol Oncol. 2006 May-Jun; (3): 222-3
- Application of genomic technologies to human prostate cancer. OMICS. 2006; (3): 261-75
- Cell-line and tissue-specific signatures of androgen receptor-coregulator transcription. J Mol Med (Berl). 2006; (11): 919-31
- Editorial comment. J Urol. 2006; (5): 2005
- Editorial comment. J Urol. 2006; (2): 472-3
- Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med. 2006; (1): e13
- Modest induction of phase 2 enzyme activity in the F-344 rat prostate. BMC Cancer. 2006: 62
- Refractory hematuria from amyloidosis successfully treated by splenectomy. Urology. 2006; (5): 1085.e13-5
- Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade. Urology. 2006; (6): 1229-34
- Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. Prostate. 2005; (2): 187-97
- Juvenile posttraumatic high-flow priapism: current management dilemmas. J Pediatr Surg. 2005; (4): E25-8
- Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer. Cancer Genomics Proteomics. 2005; (2): 97-114
- Molecular targets of doxazosin in human prostatic stromal cells. Prostate. 2005; (4): 400-10
- Positive family history of prostate cancer not associated with worse outcomes after radical prostatectomy. Urology. 2005; (2): 311-5
- Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol. 2005; (25): 6157-62
- Reg IV: a promising marker of hormone refractory metastatic prostate cancer. Clin Cancer Res. 2005; (6): 2237-43
- Resveratrol-induced gene expression profiles in human prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 2005; (3): 596-604
- The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer. Cancer Res. 2005; (18): 8118-24
- Time trends in pathologic features of radical prostatectomy--impact of family history. Urol Oncol. 2004 May-Jun; (3): 169-73
- A transcriptional profile of aging in the human kidney. PLoS Biol. 2004; (12): e427
- Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate. 2004; (3): 243-51
- Biochemical remission after resection of prostate cancer lung metastasis. Urology. 2004; (3): 584-5
- Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells. Mol Biol Cell. 2004; (2): 506-19
- Gene expression in the normal adult human kidney assessed by complementary DNA microarray. Mol Biol Cell. 2004; (2): 649-56
- Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A. 2004; (3): 811-6
- Lower body mass index is associated with a higher prostate cancer detection rate and less favorable pathological features in a biopsy population. J Urol. 2004; (6 Pt 1): 2199-202
- Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol. 2004; (3): 131-41
- Radiotherapy after radical prostatecomy: Does transient androgen suppression improve outcomes? International Journal of Radiation Oncology Biology Physics. 2004: 341-347
- Vascular invasion predicts recurrence after radical prostatectomy: stratification of risk based on pathologic variables. Urology. 2004; (4): 749-53
- Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy. Prostate-specific antigen. Urology. 2003; (2): 380-5
- Differential gene-expression patterns in genital fibroblasts of normal males and 46,XY females with androgen insensitivity syndrome: evidence for early programming involving the androgen receptor. Genome Biol. 2003; (6): R37
- Expression of FKBP12 in benign and malignant vascular endothelium: an immunohistochemical study on conventional sections and tissue microarrays. Am J Surg Pathol. 2003; (1): 58-64
- Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proc Natl Acad Sci U S A. 2003; (23): 13350-5
- Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol. 2003; (3): 925-32
- Anatomy of the rectourethralis muscle. Eur Urol. 2002; (1): 94-100
- Identification of potential prostate cancer preventive agents through induction of quinone reductase in vitro. Cancer Epidemiol Biomarkers Prev. 2002; (9): 868-75
- Microarray analysis in prostate cancer research. Curr Opin Urol. 2002; (5): 395-9
- Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. J Biol Chem. 2002; (17): 14877-83
- Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis. Prostate. 2002; (4): 269-78
- Silencing of pi-class glutathione S-transferase in MDA PCa 2a and MDA PCa 2b cells. Prostate. 2002; (4): 225-30
- Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol. 2002; (7): RESEARCH0032
- GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol. 2001; (5): 1815-26
- New molecular approaches for identifying novel targets, mechanisms, and biomarkers for prostate cancer chemopreventive agents. Urology. 2001; (4 Suppl 1): 100-2
- Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol. 2001; (6): 2034-8
- Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. Cancer Epidemiol Biomarkers Prev. 2001; (9): 949-54
- Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann N Y Acad Sci. 2001: 135-44
- Prevention of prostate cancer. Hematol Oncol Clin North Am. 2001; (3): 445-57
- Role of cytologic criteria in the histologic diagnosis of Gleason grade 1 prostatic adenocarcinoma. Hum Pathol. 2001; (4): 441-6
- GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas. Int J Oncol. 2000; (4): 663-76
- Absence of HinfI Restriction Abnormalities in Renal Oncocytoma Mitochondrial DNA. Mol Urol. 1999; (1): 1-3
- Partial nephrectomy and caval thrombectomy for renal cell carcinoma in a solitary kidney with an accessory renal vein. BJU Int. 1999; (1): 142-3
- Potent induction of carcinogen defence enzymes with sulforaphane, a putative prostate cancer chemopreventive agent. Prostate Cancer Prostatic Dis. 1999; (S3): S8
- CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 1998; (6): 531-6
- Male pelvic anatomy reconstructed from the visible human data set. J Urol. 1998; (3): 868-72
- Differentiation of colonic metaplasia from adenocarcinoma of urinary bladder. Hum Pathol. 1997; (10): 1152-7
- Methylation of the 5' CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res. 1997; (1): 35-7
- The Swedish prostate cancer paradox. JAMA. 1997; (6): 497-8
- An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res. 1996; (16): 3814-22
- Epidemiologic and molecular features of prostate carcinogenesis as clues for new prostate cancer prevention strategies Canadian Journal of Urology. 1996; (Supplement): 30-36
- Molecular staging of prostate cancer Canadian Journal of Urology. 1996; (Supplement): 80-88
- Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate. 1995; (1): 35-9
- Comparison of open and endourologic approaches to the obstructed ureteropelvic junction. Urology. 1995; (6): 791-5
- Embryonal adenoma of the kidney: case report Journal of Urology. 1995: 1473-1474
- Frequent loss of chromosome arms 8p and 13q in collecting duct carcinoma (CDC) of the kidney. Genes Chromosomes Cancer. 1995; (1): 76-80
- Molecular and chromosomal alterations in prostate cancer. Cancer. 1995: 2004-2012
- Molecular biology of prostate cancer progression. Cancer Surv. 1995: 19-32
- UPJ obstruction: assessing minimally invasive therapies. Contemp Urol. 1995; (12): 47-9, 54-5, 59-61
- Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A. 1994; (24): 11733-7
- Genetic alterations in prostate cancer. Cold Spring Harb Symp Quant Biol. 1994: 653-9
- Laparoscopic management of testicular pain after embolotherapy of varicocele. J Endourol. 1994; (5): 361-3
- Molecular biology of prostate cancer. Semin Oncol. 1994; (5): 514-21
- Mutations of the VHL tumour suppressor gene in renal carcinoma Nature Genetics. 1994: 85-90
- Genetic alterations in prostate cancer - prognostic implications? Akteulle Onkologie. 1993: 84-92
- Regional DNA Hypermethylation at D17S5 precedes 17p structural changes in the progression of renal tumors Cancer Research. 1993: 2719-2722
- Tubularized neourethra following radical retropubic prostatectomy. J Urol. 1993; (2 Pt 1): 407-9; discussion 409-10
- Tumor suppressor gene allelic loss in human renal cancers. J Urol. 1993; (4): 1278-83
- Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum. Neurosci Lett. 1985; (3): 259-64
Help
Trial Administration